Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma

Singer, S., Socci, N. D., Ambrosini, G., Sambol, E., Decarolis, P., Wu, Y., O'Connor, R., Maki, R., Viale, A., Sander, C., Schwartz, G. K., Antonescu, C. R. (July 2007) Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res, 67 (14). pp. 6626-36. ISSN 0008-5472 (Print)0008-5472 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/17638873
DOI: 10.1158/0008-5472.CAN-07-0584

Abstract

Classification of liposarcoma into three biological types encompassing five subtypes, (a) well-differentiated/dedifferentiated, (b) myxoid/round cell, and (c) pleomorphic, based on morphologic features and cytogenetic aberrations, is widely accepted. However, diagnostic discordance remains even among expert sarcoma pathologists. We sought to develop a more systematic approach to liposarcoma classification based on gene expression analysis and to identify subtype-specific differentially expressed genes that may be involved in liposarcoma genesis/progression and serve as potential therapeutic targets. A classifier based on gene expression profiling was able to distinguish between liposarcoma subtypes, lipoma, and normal fat samples. A 142-gene predictor of tissue class was derived to automatically determine the class of an independent validation set of lipomatous samples and shows the feasibility of liposarcoma classification based entirely on gene expression monitoring. Differentially expressed genes for each liposarcoma subtype compared with normal fat were used to identify histology-specific candidate genes with an in-depth analysis of signaling pathways important to liposarcoma pathogenesis and progression in the well-differentiated/dedifferentiated subset. The activation of cell cycle and checkpoint pathways in well-differentiated/dedifferentiated liposarcoma provides several possible novel therapeutic strategies with MDM2 serving as a particularly promising target. We show that Nutlin-3a, an antagonist of MDM2, preferentially induces apoptosis and growth arrest in dedifferentiated liposarcoma cells compared with normal adipocytes. These results support the development of a clinical trial with MDM2 antagonists for liposarcoma subtypes which overexpress MDM2 and show the promise of using this expression dataset for new drug discovery in liposarcoma.

Item Type: Paper
Uncontrolled Keywords: Adipocytes/metabolism Adipose Tissue/metabolism Cell Differentiation Cell Proliferation Cluster Analysis Disease Progression *Gene Expression Profiling *Gene Expression Regulation, Neoplastic Humans Imidazoles/metabolism Liposarcoma/*classification/*metabolism Models, Biological Oligonucleotide Array Sequence Analysis Piperazines/metabolism Reverse Transcriptase Polymerase Chain Reaction Soft Tissue Neoplasms/*classification/*metabolism
Subjects: organs, tissues, organelles, cell types and functions > cell types and functions > cell functions > cell differentiation
organs, tissues, organelles, cell types and functions > cell types and functions > cell functions > cell proliferation
diseases & disorders > cancer > drugs and therapies
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > genes, structure and function > gene expression
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 15 July 2007
Date Deposited: 26 Oct 2016 16:46
Last Modified: 26 Oct 2016 16:46
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33680

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving